Spoiler alert: no one is.

With vaccine authorizations hitting the 5–12 year-old age group soon, we’ll see an uptick in the overall vaccination rate in the US, but of course there remain tens of millions people who are eligible for the vaccine who remain unvaccinated. This is a problem. …

Alternate dosing intervals and mixing-and-matching vaccines really just give an illusion of control. But it may be worth it anyway.

Like many people in healthcare, I’ve been fielding questions from friends, family members, and the public about COVID for the past, well, almost two years. And, broadly, they fit in just a few categories.

There are the “when will we go back to normal?” questions.

There are the “Is [blank]…

Vaccination (and even prior infection) protects susceptible family members.

We’ve talked a lot about the concept of herd immunity during this pandemic, but mostly in the context of huge populations — herd immunity at the country level or even the world. …

The long-existing gap in mortality rates by race widened in 2020.

The COVID pandemic has shone a light on so many aspects of our culture, from our woefully inadequate public health infrastructure, to the way that political ideologies can shape interpretations of data. …

New study leveraging random sampling has some surprising results.

This week, we’re going to talk about COVID symptoms. I know, we’re almost two years into this pandemic — why do we need to talk about symptoms now? The short answer is because testing isn’t ubiquitous enough. …

Modest benefit, minimal risk

The COVID controversy du jour seems to center firmly around the booster shot.

Last week the Vaccine and Related Biological Products Advisory Committee at the FDA met to review data on the safety and efficacy of a potential third dose of the Pfizer vaccine.

I want to review the data…

New study shows elevated risk, but it may be due to elevated surveillance.

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr. F. Perry Wilson of the Yale School of Medicine.

September 11th, 2001 was the day I learned the difference between the French word attaque, which you would use if someone attacked someone else, and…

The antidepressant appears to have some ability to prevent worsening in outpatients with COVID-19

By virtually all metrics, vaccine development for COVID-19 has been an astonishing success. But when it comes to therapeutics, the picture is much more mixed. This means the tip of the spear of the battle against coronavirus is and will remain vaccination, but, as you know, not everyone is getting…

The rare condition can be devastating, but fortunately most kids recover.

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr. F. Perry Wilson of the Yale School of Medicine.

Kids are back in school throughout the country now, and, in many locations, the Delta variant of coronavirus is highly prevalent — raising the possibility…

It isn’t age. It’s how long you wait to get tested.

Kids are getting COVID, and with the highly-infectious Delta variant still surging in the US, I have a lot of concern about outbreaks once all the children are back in school.

Of course, while some kids get very sick from COVID-19, most do not, thankfully. But kids tend to live…

F. Perry Wilson, MD MSCE

Writing about medicine, science, statistics, and the abuses thereof. Commentator at Medscape. Associate Professor of Medicine at Yale University.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store